Study of Pembrolizumab and Olaparib in Bile Duct Cancer

Summary

The investigators propose an open label, one-arm study to assess the safety and efficacy of olaparib and pembrolizumab in patients with cholangiocarcinoma who have progressed on or cannot tolerate gemcitabine-based therapy.

Timeline

Start

2020-04-01

Primary completion

2023-07-16

Completion

2024-12-19

Publications

• Sadagopan N, Wang H, Yin C, Weinberg BA, Noel MS, Mukherji R, Geng X, Marshall JL, He AR. A phase II single-arm study of combination pembrolizumab and olaparib in the treatment of patients with advanced biliary tract cancer. NPJ Precis Oncol. 2025 Jul 8;9(1):229. doi: 10.1038/s41698-025-01009-1.

Drugs

Indications